← Research library

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis

Comparison in people · 2017

What was studied
218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
Main finding
At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

TSH at month four · Standard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09. · The table marks both adjunctive arms as significantly different from standard care.

Reported findings and study design

89 patients received standard treatment, 42 added Tireogen and 87 added Tireogen plus Endoluten. The reported schedules were two Tireogen capsules daily and one Endoluten capsule every three days for four months. Capsule mass is unspecified. The levothyroxine unit in the reproduction is anomalous.

Population or model 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.

Results · Authors’ conference report reproduction, methods and Table 1, matched to the published abstract
MeasureResultComparison, timing and statistics
TSH at month fourStandard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09.The table marks both adjunctive arms as significantly different from standard care.
Anti-thyroglobulin antibodies83.32 ± 3.28, 77.41 ± 1.18 and 18.91 ± 1.65 IU/L in the three groups, respectively.The table marks both adjunctive arms. The narrative describes no antibody effect with Tireogen alone.
Anti-thyroid peroxidase antibodies361.24 ± 12.4, 357.23 ± 11.41 and 29.16 ± 2.54 IU/L, respectively. The table gives no significance mark for this row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The design leaves allocation unspecified and the table gives one shared baseline.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • Allocation, masking and separate baseline values are unspecified. There was no Endoluten-only arm.
  • The table marks an anti-thyroglobulin difference for Tireogen alone, while the narrative says Tireogen alone did not affect antibodies. The anti-TPO row gives no significance mark.
  • The reproduction prints an anomalous levothyroxine unit. The exact background dose is uncertain.

Source details

Published conference abstract with author report

Published 2017 conference abstract and authors’ reproduced report, PDF pages 16–17. The 2015 and 2017 presentations describe the same study program.

Sources checked

Citation

Human comparative studyEnglish abstract

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov. Tireogen and Endoluten as adjuncts in autoimmune thyroiditis Innovation in Aging. 2017;1(Suppl 1):324. PMCID PMC6243877.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards